Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOICE: Integrating Long-Acting Injectable Treatment for HIV and OUD
NCT05991622Phase 2Withdrawn
- Sponsor
- Rhode Island Hospital
- Start
- Apr 2022
- Primary completion
- Aug 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of cabotegravir + rilpivirine, buprenorphine in human immunodeficiency virus infection (HIV), opioid use disorder (OUD), sponsored by Rhode Island Hospital. Planned start Apr 2022; status: withdrawn.
02
Drugs
cabotegravir + rilpivirinebuprenorphine
03
Conditions
human immunodeficiency virus infection (HIV)opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05991622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05991622.